Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

• Autori principali: Adrin Dadkhah (Autore), Sebastian Georg Wicha (Autore), Nicolaus Kröger (Autore), Alexander Müller (Autore), Christoph Pfaffendorf (Autore), Maria Riedner (Autore), Anita Badbaran (Autore), Boris Fehse (Autore), Claudia Langebrake (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2022-05-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment to date. Busulfan-based conditioning regimens are commonly used, although high inter-individual variability (IIV) in busulfan drug exposure makes individual dose select...